logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Swedish Orphan Biovitrum AB (publ) drugs

    FiltersReset Filters
    6 results

    • gamifant

      (emapalumab-lzsg)
      Swedish Orphan Biovitrum AB (publ)
      Usage: GAMIFANT is indicated for treating adults and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent, or progressive disease or cannot tolerate conventional HLH therapy.

    • kepivance

      (palifermin)
      Swedish Orphan Biovitrum AB (publ)
      Usage: Kepivance is indicated to reduce the incidence and duration of severe oral mucositis in patients with hematologic malignancies undergoing myelotoxic therapy with autologous stem cell support. It serves as supportive care for preparative regimens likely to cause ≥ WHO Grade 3 mucositis.

    • kineret

      (anakinra)
      Swedish Orphan Biovitrum AB (publ)
      Usage: KINERET is indicated for reducing signs and symptoms and slowing structural damage in moderately to severely active rheumatoid arthritis in adults who have failed previous DMARDs. It is also used to treat Neonatal-Onset Multisystem Inflammatory Disease and Deficiency of Interleukin-1 Receptor Antagonist.

    • orfadin

      (Nitisinone)
      SWEDISH ORPHAN BIOVITRUM AB (PUBL)
      Usage: ORFADIN® is indicated for treating adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1), alongside dietary restriction of tyrosine and phenylalanine.

    • orfadin

      (nitisinone)
      Swedish Orphan Biovitrum AB (publ)
      Usage: ORFADIN® is indicated for treating adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1), and it should be used alongside a diet that restricts tyrosine and phenylalanine intake.

    • synagis

      (palivizumab)
      Swedish Orphan Biovitrum AB (publ)
      Usage: Synagis is indicated for preventing serious lower respiratory tract disease caused by RSV in pediatric patients: 1) born prematurely (≤35 weeks) and ≤6 months at RSV season start; 2) with BPD requiring treatment and ≤24 months; 3) with significant CHD and ≤24 months at RSV season start.